“The Great Plumping: Boomers and Bold Self-Care Spark the Surprising Rise of Injectables”
**The Booming Market of Cosmetic Injectables: Galderma’s Rise to Success**
The beauty and cosmetic industry has seen a significant shift in recent years, with baby boomers and individuals suffering from weight loss-related facial sagging turning to injectable cosmetic treatments in droves. Swiss-based company Galderma, a leading player in the neuromodulator injections and fillers market, has been at the forefront of this trend, reporting a “significant increase” in consumers over the age of 60 opting for beauty treatments.
**The Rise of Galderma**
Founded in 2019 after Nestlé sold its skin health unit to a consortium of investors, Galderma has seen its shares soar in the past year, more than doubling in value to 108.50 Swiss francs per share. The company’s net sales rose 9.2% to $3.2 billion in the nine months ended September 2024, driven by its two largest segments: Dermatology Skin Care and cosmetic injectables.
Galderma’s most popular filler among weight-loss drug users is Sculptra, a product originally developed for HIV patients experiencing rapid weight loss. The company’s chief executive, Flemming Ernskov, credits the rise of weight-loss drugs like Ozempic for boosting filler sales, particularly in areas with high penetration of GLP-1 drugs such as the Middle East and North America.
**The Impact of Weight-Loss Drugs on the Beauty Industry**
The emergence of weight-loss drugs like Ozempic has created a new demand for facial treatments, as patients experience facial sagging as they lose weight. According to Ernskov, if patients lose 8-10 kilograms or more, they start to experience facial sagging, necessitating the use of fillers. This trend has driven sales of Galderma’s Sculptra product, making it the company’s best-selling filler brand in the United States.
**Competition in the Market**
Galderma faces stiff competition in the market, with U.S. company AbbVie holding the lead in the category. However, Galderma is closing the gap, with its Dysport brand becoming a popular choice among U.S. dermatologists. In fact, 80% of U.S. doctors use Dysport in their clinics, compared to 20% for Botox.
**Galderma’s Strategy for Success**
To further increase its market share, Galderma is launching new products, such as Nemluvio, a treatment for atopic dermatitis, which recently received approval from the U.S. Food and Drug Administration. The company also plans to expand its presence in the U.S. market with the launch of new fillers designed for people who want to appear to have better bone structure, such as men who want a stronger jaw.
**Conclusion**
The cosmetic injectables market is booming, driven by an aging population and the rise of weight-loss drugs. Galderma, a leader in the neuromodulator injections and fillers market, has seen significant growth in recent years, thanks to its popular products like Sculptra and Dysport. As the company continues to launch new products and expand its presence in the market, it is likely to remain a major player in the industry.
**Frequently Asked Questions (FAQs)**
1. **What is Galderma’s most popular filler brand in the United States?**
Galderma’s Sculptra is its most popular filler brand in the United States, particularly among users of weight-loss drugs.
2. **What is the market size of the neuromodulator injections and fillers market?**
The market size of the neuromodulator injections and fillers market is $9 billion.
3. **What is the role of weight-loss drugs in driving sales of Galderma’s fillers?**
Weight-loss drugs like Ozempic have created a new demand for facial treatments, as patients experience facial sagging as they lose weight, leading to increased sales of Galderma’s fillers.
4. **What are some of Galderma’s new products in development?**
Galderma has launched new products like Nemluvio, a treatment for atopic dermatitis, and plans to launch new fillers designed for people who want to appear to have better bone structure.
5. **What is Galderma’s competitive advantage in the market?**
Galderma’s competitive advantage lies in its popular products like Sculptra and Dysport, which have gained significant market share in the U.S. dermatology market.
**Json-LD FAQ Page**
“`json
{
“@context”: “https://schema.org”,
“mainEntity”: {
“name”: “Galderma: The Rise of Cosmetic Injectables”,
“description”: “Galderma has seen significant growth in the cosmetic injectables market, driven by an aging population and weight-loss drugs.”,
“FAQs”: [
{
“name”: “What is Galderma’s most popular filler brand in the United States?”,
“answer”: “Galderma’s Sculptra is its most popular filler brand in the United States, particularly among users of weight-loss drugs.”
},
{
“name”: “What is the market size of the neuromodulator injections and fillers market?”,
“answer”: “The market size of the neuromodulator injections and fillers market is $9 billion.”
},
{
“name”: “What is the role of weight-loss drugs in driving sales of Galderma’s fillers?”,
“answer”: “Weight-loss drugs like Ozempic have created a new demand for facial treatments, as patients experience facial sagging as they lose weight, leading to increased sales of Galderma’s fillers.”
},
{
“name”: “What are some of Galderma’s new products in development?”,
“answer”: “Galderma has launched new products like Nemluvio, a treatment for atopic dermatitis, and plans to launch new fillers designed for people who want to appear to have better bone structure.”
},
{
“name”: “What is Galderma’s competitive advantage in the market?”,
“answer”: “Galderma’s competitive advantage lies in its popular products like Sculptra and Dysport, which have gained significant market share in the U.S. dermatology market.”
}
]
}
}
“`
**Conclusion**
In conclusion, Galderma’s rise to success in the cosmetic injectables market is a testament to the company’s innovative products and strategic expansion in the market. As the company continues to develop new products and expand its presence in the industry, it is poised to remain a major player in the market for years to come.
